In vitro and in vivo studies on prostate cancer cell lines and tumor xenografts with varying basal PSMA expression levels and androgen dependencies showed an upregulation of PSMA by 1.5- to 25-fold following exposure to enzalutamide [28–30]. Here, FOLH1 is linked to prostate carcinoma.